Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells

Biotechnology and Bioengineering

Volumn 102, Issue 2, 2009, Pages 521-534

  Yang, Liying ^a   Lang, James C ^b   Balasubramanian, Priya ^a   Jatana, Kris R ^b   Schuller, David ^b   Agrawal, Amit ^b   Zborowski, Maciej ^c   Chalmers, Jeffrey J ^a,d  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d University Cell Analysis and Sorting Core   (United States)

Author keywords

Circulating tumor cells; Immunocytochemistry; Immunomagnetic cell separation; RT PCR; Squamous cell carcinoma of the head and neck (HNSCC)

Indexed keywords

CIRCULATING TUMOR CELLS; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC CELL SEPARATION; RT-PCR; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (HNSCC);

ABERRATIONS; BLOOD; CELL CULTURE; COSMIC RAYS; CYTOLOGY; LABELING; OPTICAL PROPERTIES; OPTIMIZATION; TEMPERATURE CONTROL; TUMORS;

CELLS;

ARTICLE; CELL COUNT; CELL ISOLATION; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; BLOOD; CHEMISTRY; ERYTHROCYTE; HEAD AND NECK TUMOR; HEMOLYSIS; METHODOLOGY; PATHOLOGY; STAINING; TUMOR EMBOLISM;

CD45 ANTIGEN;

ANTIGENS, CD45; ERYTHROCYTES; HEAD AND NECK NEOPLASMS; HEMOLYSIS; HUMANS; IMMUNOMAGNETIC SEPARATION; NEOPLASTIC CELLS, CIRCULATING; STAINING AND LABELING;

EID: 58249094045     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22066     Document Type: Article

References (37)

1. Bagnato A, Rosano L. Epithelial-mesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis. Cells Tiss Organs 2007. 185:85-94.
2. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP. 2007. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24:587-597.
3. Brandt BH, Schmidt H, de Angelis G, Zänker KS, 2001. Predictive laboratory diagnostics in oncology utilizing blood-borne cancer cells - Current best practice and unmet needs. Cancer Lett 162:S11 -S16.
4. Braun S, Pantel K. 2001. Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. Oncologist 6(2):125-132.
5. Brazin R, Lemieux R, Tremblay T, St-Amour I. 2004. Tetramolecular immune complexes are more effectient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 127:90-96.
6. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transitions in development and disease. Cells Tiss Organs 2007. 185:7-9.
7. Chalmers JJ, Xiong Y, Shao M, Tong X, Farag S, Zborowski M. submitted. Quantification of non-specific binding of magnetic nanoparticles: Implication for detection and magnetic cell separation. Biotechnol Bioeng.
8. Chosy J, Melnik K, Comella K, Zborowski M, Chalmers JJ. 2003. Characterization of antibody binding to three cancer-related antigens using flow cytometry and cell tracking velocimetry. Biotechnol Bioeng 82:340-351.
9. Christiansen JJ, Rajasekaran AK. 2006. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319-8326.
10. Green MC, Murray JL, Hortobagyi GN. 2000. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26(4):269-286.
11. Ko Y, Grunewald E, Totzke G, Klinz M, Fronhoffs S, Gouni-Berthold I, Sachinidis A, Vetter H. 2000. High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: A model for the analysis of illegitimate gene expression. Oncology 59:81-88.
12. Kokkinos MI, Wafai R, wong MK, Newgreen DF, Thompson EW, Waltham M. 2007. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tiss Organs 185:191-203.
13. Lansdorp PM, Aalberse RC, Bos R, Schutter WG, Van Bruggen EF. 1986. Cyclic tetramolecular complexes of monoclonal antibodies: A new type of cross-linking reagent. Eur J Immunol 16(6):679-683.
14. Lara O, Tong X, Zborowski M, Chalmers JJ. 2004. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 32(10):891-904.
15. Lara O, Tong X, Zborowski M, Farag S, Chalmers JJ. 2006. Comparison of two immmunomagnetic separation methodologies to deplete T-cells from human blood samples. Biotechnol Bioeng 94(1):66-80.
16. McCloskey K, Chalmers JJ, Zborowski M. 2003a. Magnetic cell separation: Characterization of magnetophoretic mobility. Anal Chem 75(4):6868-6874.
17. McCloskey K, Moore L, Hoyos M, Rodrigues A, Chalmers JJ, Zborowski M. 2003b. Magnetic cell separation is a function of antibody binding capacity (ABC). Biotechnol Prog 19(3):899-907.
18. McKenzie SB. 1996. Textbook of hematology. Baltimore: Williams and Wilkins.
19. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. 2006. The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 12:4605-4613.
20. Pantel K, Brakenhoff RH. 2004. Dissecting the metastatic cascade. Nat Rev 4:448-456.
21. Partridge M, Brkenhoff R, Phillips E. 2003. Detection ofrare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure. Clin Cancer Res 9:5287-5294.
22. Paterlini-Brechot P, Benali NL. 2007. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett 253:180-204.
23. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, Uhr JW. 1998. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci 95:4589-4594.
24. Ralph SJ, Thomas ML, Morton CC, Trowbridge IS. 1987. Structural variants of human T200 glycoprotein (leukocyte-common antigen). EMBO J 6:1251-1257.
25. Riethdorf S, Fritsche H, Muller V. 2007. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the Cellsearch system. Clin Cancer Res 13(3):920-928.
26. Sarrio D, Rodrigues-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008. 68:989-997.
27. Sun L, Zborowski M, Moore L, Chalmers JJ. 1998. Continuous flow-through immunomagnetic cell separation in a quadrupole field. Cytometry 33:469-475.
28. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005. 65:5996-6000.
29. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2:442-454.
30. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions Natt. Rec Mol Cell Biol 7:131-142.
31. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastatis: A role for epithelial-mesenchymal transition? Cancer Res 2005. 65:5991-5995.
32. Tong X, Yang L, Lang JC, Zborowski M, Chalmers JJ. 2007a. Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytometry B Clin Cytom 72(5):310-323.
33. Tong X, Xiong Y, Zborowski M, Farag SS, Chalmers JJ. 2007b. A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation. Exp Hematol 35(10):1613-1622.
34. Zborowski M, Ostera GR, Moore LR, Milliron S, Chalmers JJ, Schechter AN. Red blood cell magnetophoresis. Biophys J 84:2638-2645. 2003.
35. Zen H, Nakashiro KI, Shintani S, Aramoto T, Hamakawa H. 2003. Detection of circulating cancer cells in human oral squamous cell carcinoma. Int J Oncol 23(3):605-610.
36. Zhang H, Zborowski M, Williams PS, Chalmers JJ. 2005. Establishment and implications of a characterization method for magnetic nanoparticles using Cell Tracking Velocimetry and magnetic susceptibility modified solutions. Analyst 130:514-527.
37. Zhang H, Williams PS, Zborowski M, Chalmers JJ. 2006. Reduction of binding affinities/avidities of Antibody-Antigen and Strepadvidin-biotin: Quantification and Scale-up implications. Biotechnol Bioeng 95:812-829.